Keyword: AbbVie

It seems logical: pharmas teaching doctors' staff how to handle patients using their drugs. But a slew of companies are discovering it's not so simple.

Gilead's hepatitis C sales have eroded big-time, and the company is taking an unusual new tack that might deliver its drugs to new patients.

Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.

Pharma companies Pfizer, Merck and Johnson & Johnson are dodging billions of dollars of tax payments annually, an Oxfam report concluded.

The entry of a fifth biosimilar rival to Humira in Europe could feed fears of a bigger-than-predicted impact on AbbVie.

A California lawsuit alleges that AbbVie grew Humira sales through kickbacks and nurse "ambassadors" at the expense of patient safety.

Can Humira really avoid the biosimilar bloodletting that's hit Merck's Remicade and Pfizer's Enbrel in the EU? Execs say yes. Analysts now aren't so sure.

Could Boehringer Ingelheim and its scrappy biosimilar defense turn out to be AbbVie's Humira stumbling block?

AndroGel plaintiffs and drugmaker AbbVie have progressed in settlement talks, and a judge stayed further proceedings so they can work out a deal.